Developing Countries Vaccine Manufacturers Network
DCVMN is a voluntary Geneva-based alliance of 48 vaccine manufacturers from 17 developing countries, coordinating regulatory harmonization, technology transfer, and training across all six WHO regions. Members supply over 150 countries and supported 19 of Gavi's 20 vaccine programs.
- Company typePrivate
- Founded2000
- HeadquartersNyon, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Developing Countries Vaccine Manufacturers Network does
Developing Countries Vaccine Manufacturers Network (DCVMN), legally DCVMN International, is a voluntary public health-driven alliance founded in 2000 and headquartered in Geneva, Switzerland. The organization comprises 48 public and private vaccine manufacturers across 17 developing countries spanning all six WHO regions, functioning as a collaborative platform for regulatory harmonization, technology transfer, South-South cooperation, and advocacy for vaccine equity. DCVMN does not manufacture or sell vaccines directly; instead, it operates through six expert working groups (Regulatory Affairs, Pharmacovigilance, Supply Chain and Traceability, 3Rs alternative testing, Clinical Development, Manufacturing Sciences), the PSPT Consortium (established 2020 to replace animal-based pertussis testing), the Technical Collaborations Portal (for sharing member manufacturing capacity), and a Moodle-based e-learning platform including a novel VR training module for the Monocyte Activation Test developed with Istituto Superiore di Sanità and Lucerne University. Annual General Meetings (26th in Bali October 2025, 27th scheduled for Beijing September 2026) serve as the flagship convening events.
The alliance's economic value flows through its member manufacturers rather than its own balance sheet. Members supply vaccines to over 150 countries and accounted for more than 60% of global COVID-19 vaccine doses during the pandemic (over 9 billion doses cumulatively), with Bio Farma alone holding 3.5+ billion doses/year production capacity. Members support 19 of Gavi's 20 vaccine programs, with 12 supplied solely by DCVMN members, and rely on WHO prequalification, UNICEF Supply Division, and PAHO Revolving Fund as primary procurement channels. Revenue for the DCVMN secretariat itself derives from membership dues and corporate sponsorships (including Tofflon, Cytiva, Biozeen, GEA, WuXi Vaccines, Adjuvant Capital, and others), but is not publicly disclosed. Strategic leadership is provided by CEO Rajinder Suri and a rotating Board (Indonesia through Bio Farma chaired 2023-2025), with operational activity supported by a small 1-10 employee secretariat. Recent member regulatory milestones include WHO prequalification for FLU-M influenza and GreenSignal BCG vaccines, plus NMPA approvals for Cecolin 9 (HPV) and Rotasiro (hexavalent rotavirus).
Developing Countries Vaccine Manufacturers Network firmographics
Firmographics- Name
- Developing Countries Vaccine Manufacturers Network
- Legal name
- DCVMN International
- Website
- https://dcvmn.org
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DCVMN is a voluntary Geneva-based alliance of 48 vaccine manufacturers from 17 developing countries, coordinating regulatory harmonization, technology transfer, and training across all six WHO regions. Members supply over 150 countries and supported 19 of Gavi's 20 vaccine programs.
- Ownership category
- akta.pro rank
Developing Countries Vaccine Manufacturers Network industry classification
Industry- Product category
- Vaccine Manufacturing Alliance
- NAICS
- Business Associations (813910), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Global Immunization & Vaccine Access Alliances (HLAJAKAK)
- akta.pro secondary industries
- Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs (HLAJAHAK), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)
Keywords
Where Developing Countries Vaccine Manufacturers Network is headquartered
LocationHeadquarters
- HQ city
- Nyon
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Developing Countries Vaccine Manufacturers Network business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&, D, Marketing or Sales, Others
Revenue model
- Network Membership Dues: DCVMN is a voluntary alliance of vaccine manufacturers. Revenue appears to come from membership contributions and sponsorships to fund the secretariat operations, working groups, and educational programs.
- Member Vaccine Sales: Member manufacturers supply vaccines to over 150 countries worldwide. The network facilitates these partnerships but does not directly generate revenue from vaccine sales.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Developing Countries Vaccine Manufacturers Network product offering
Product offeringCore offering
DCVMN is a voluntary public-health-driven alliance of 48 vaccine manufacturers from 17 developing countries, headquartered in Geneva, Switzerland. It facilitates regulatory harmonization, technology transfer, workforce training, and advocacy to expand equitable global access to high-quality vaccines. The alliance operates an e-learning platform, VR-based training tools, expert working groups, the PSPT research consortium, and an annual general meeting to strengthen members' manufacturing capacity and pandemic preparedness.
Product overview
DCVMN operates as a voluntary public health-driven alliance of vaccine manufacturers from developing countries. Rather than a unified product platform, DCVMN offers a portfolio of collaborative programs and services: its E-learning Platform (Moodle) and VR Training Modules provide innovative workforce development; the Technical Collaborations Portal enables members to share manufacturing capacities; the PSPT Consortium facilitates alternative testing methods research; six Expert Working Groups drive peer collaboration in regulatory affairs, pharmacovigilance, supply chain, 3Rs, and clinical development; and Annual General Meetings convene the global vaccine community. The COVID-19 Information Bank serves as a resource hub during health emergencies.
Differentiator
Problem solved
Functional benefit
Products and services
- E-learning Platform (Moodle)
Quantifiable outcome
- 60%+ of global COVID-19 vaccine production supplied by DCVMN members during the pandemic
- +3 more outcomes
Companies that use Developing Countries Vaccine Manufacturers Network
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Developing Countries Vaccine Manufacturers Network technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability2 records
Feature5 records
Developing Countries Vaccine Manufacturers Network partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and major.
- Bio Farma IndonesiacoreBio Farma served as Chair of DCVMN for 2023-2025 period, hosting the 26th DCVMN AGM in Bali. Bio Farma achieved WHO Emergency Use Listing for nOPV2 vaccine in 2020, demonstrating developing-country manufacturers can meet international quality standards. The company supplies vaccines to over 150 countries with production capacity exceeding 3.5 billion doses per year.
- World Health Organization (WHO)coreWHO collaborates with DCVMN on regulatory harmonization, prequalification, Emergency Use Listing procedures, and pandemic preparedness. DCVMN members participate in WHO working groups and initiatives including the i-MCM-Net for medical countermeasures.
- Gavi, the Vaccine AlliancecoreDCVMN members support 19 of Gavi's 20 programs, with 12 vaccines supplied solely by DCVMN members. Gavi's advance market commitment and financing mechanisms enable DCVMN manufacturers to supply affordable vaccines to developing countries.
- CEPI (Coalition for Epidemic Preparedness Innovations)coreCEPI partners with DCVMN on pandemic preparedness, H5N1 vaccine readiness workshops, and manufacturing capacity strengthening. DCVMN CEO participates in CEPI-led initiatives for the 100 Days Mission.
- PATHmajorDCVMN and PATH collaborate on pharmacovigilance e-workshops, packaging technology workshops, and the CHAI Go-to-market toolbox for developing country manufacturers.
- Medicines Patent PoolmajorThe Medicines Patent Pool implements WHO's C-TAP initiative. DCVMN member Medigen Vaccine Biologics Corp out-licensed COVID-19 vaccine technology to C-TAP/MMP, enabling technology transfer and staff training for broader vaccine availability.
- Istituto Superiore di Sanità (ISS), ItalymajorISS collaborated on the Pertussis Serological Potency Test (PSPT) project and the Monocyte Activation Test (MAT) VR training module development, providing scientific expertise for alternative vaccine testing methods.
- Intravacc, NetherlandsmajorIntravacc contributed to the PSPT project for pertussis vaccine testing alternatives, working with DCVMN members on coating antigen production and characterization.
- Lucerne University of Applied Sciences and Arts (HSLU)majorCollaborated with DCVMN and ISS to develop VR training tools for Monocyte Activation Test, providing hands-on laboratory experiences using virtual reality technology.
- Indian Council of Medical Research (ICMR)majorICMR and CEPI co-organized the H5N1 Vaccine Readiness Workshop in New Delhi, bringing together DCVMN and industry stakeholders to assess India's R&D and manufacturing pathways for pandemic preparedness.
- Africa CDCcoreAfrica CDC collaborates with DCVMN on workforce development, with DCVMN's Tech Transfer Training programs delivering programs with ~25% African participation, including an Africa-focused edition developed with Africa CDC.
- Hilleman LaboratoriesmajorDCVMN developed Tech Transfer Training (train-the-trainers) programs with Hilleman Laboratories, with five programs delivered training 70+ professionals across developing countries.
- IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)majorIFPMA representatives participate routinely in DCVMN Regulatory Working Group meetings. The groups collaborate on publications and joint proposals to WHO for regulatory harmonization.
- GS1majorGS1 standards for traceability and barcoding are promoted through the DCVMN Supply Chain Working Group, with pilot studies on primary and secondary packaging barcoding across six member companies.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Developing Countries Vaccine Manufacturers Network competitors and assessment
Company assessmentOthers
- WHO Prequalification Programme: WHO programme that qualifies vaccines for UN agency procurement. Functions as a regulatory gatekeeper that DCVMN members must work through; conceptually adjacent as a vaccine access enabler though structurally distinct.
- Serum Institute of India: World's largest vaccine manufacturer by doses and a DCVMN member peer in scale. Although a member rather than peer, Serum Institute represents the upper bound of developing-country vaccine manufacturing capability and is often compared with DCVMN's collective footprint.
- Gavi, the Vaccine Alliance: Public-private partnership funding immunization in lower-income countries. While not a peer organization, Gavi is the principal downstream customer/procurement channel for DCVMN members and shapes member revenue trajectories.
- CEPI (Coalition for Epidemic Preparedness Innovations): Global partnership financing vaccine development against epidemic threats. Functions as a partnership counterparty for DCVMN on pandemic preparedness rather than a direct competitor; collaborates via the 100 Days Mission and H5N1 readiness workshops.
- Bill & Melinda Gates Foundation: Major funder of global vaccine access, Gavi, and vaccine manufacturers in developing countries. Not a peer organization but a critical ecosystem stakeholder whose funding priorities shape DCVMN member opportunities.
Broad incumbents
- BIO (Biotechnology Innovation Organization): Large US-based biotech industry trade association. Comparable as a membership-driven industry advocacy organization representing companies in biopharmaceuticals and vaccines, though broader in scope (all biotech) and serving developed-market members primarily.
- PhRMA (Pharmaceutical Research and Manufacturers of America): US pharma industry association. Comparable as a national-level pharmaceutical industry alliance engaging regulators and policy makers, but PhRMA represents the largest multinational innovators rather than developing-country manufacturers.
Emerging players
- African Vaccine Manufacturing Initiative (AVMI): African-focused vaccine manufacturing advocacy network. Comparable as an emerging-market vaccine manufacturer alliance with a narrower geographic scope than DCVMN, focused exclusively on African capacity building.
Direct peers
- International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Global pharma industry association representing innovative biopharmaceutical companies and vaccine manufacturers. Most direct functional peer to DCVMN — both serve as industry conveners engaging WHO, but IFPMA represents multinational incumbents while DCVMN represents developing-country manufacturers.
Regional players
- Vaccines Europe: European vaccine industry group within EFPIA representing major European vaccine manufacturers. Comparable as a regional vaccine manufacturer alliance, but focused on Europe rather than developing countries.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Developing Countries Vaccine Manufacturers Network social profiles
Digital presenceDeveloping Countries Vaccine Manufacturers Network compliance and trust
Trust signalCompliance10 records
Developing Countries Vaccine Manufacturers Network financial estimates
Financial estimateRevenue estimate
Valuation estimate
Developing Countries Vaccine Manufacturers Network leadership team
Management profileNumber of profiles
Profiles1 record
Developing Countries Vaccine Manufacturers Network funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Developing Countries Vaccine Manufacturers Network M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Developing Countries Vaccine Manufacturers Network
What does Developing Countries Vaccine Manufacturers Network do?
DCVMN is a voluntary public-health-driven alliance of 48 vaccine manufacturers from 17 developing countries, headquartered in Geneva, Switzerland. It facilitates regulatory harmonization, technology transfer, workforce training, and advocacy to expand equitable global access to high-quality vaccines. The alliance operates an e-learning platform, VR-based training tools, expert working groups, the PSPT research consortium, and an annual general meeting to strengthen members' manufacturing capacity and pandemic preparedness.
Is Developing Countries Vaccine Manufacturers Network a public or private company?
Developing Countries Vaccine Manufacturers Network is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Developing Countries Vaccine Manufacturers Network founded?
Developing Countries Vaccine Manufacturers Network was founded in 2000. It employs 11 to 50 people.
Where is Developing Countries Vaccine Manufacturers Network based?
Developing Countries Vaccine Manufacturers Network is headquartered in Nyon, Switzerland, in the Europe region.
How does Developing Countries Vaccine Manufacturers Network make money?
Two revenue lines are on record. Network Membership Dues are the primary driver. The others are member Vaccine Sales.
Who are Developing Countries Vaccine Manufacturers Network's main competitors?
Others on record are WHO Prequalification Programme, Serum Institute of India, Gavi, the Vaccine Alliance, CEPI (Coalition for Epidemic Preparedness Innovations) and Bill & Melinda Gates Foundation. Broad incumbents are BIO (Biotechnology Innovation Organization) and PhRMA (Pharmaceutical Research and Manufacturers of America). African Vaccine Manufacturing Initiative (AVMI) is listed as an emerging player. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is listed as a direct peer. Vaccines Europe is listed as a regional player.
Does Developing Countries Vaccine Manufacturers Network have an API?
No public API is recorded for Developing Countries Vaccine Manufacturers Network.
What industry is Developing Countries Vaccine Manufacturers Network in?
Developing Countries Vaccine Manufacturers Network's product category is Vaccine Manufacturing Alliance. Its primary akta.pro industry code is HLAJAKAK, Global Immunization & Vaccine Access Alliances, with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 813910 and its SIC code is 2834.